2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W662576
    KVD-001 1417691-95-2 99.73%
    KVD-001 is a potent plasma kallikrein inhibitor. KVD-001 can be used for diabetic macular edema research.
    KVD-001
  • HY-W685943
    Heptaminol 372-66-7 ≥98.0%
    Heptaminol is a fatty amine with pressor properties and a potential antihypotension agent. Heptaminol is also a competitive inhibitor of norepinephrine uptake and an inhibitor of nicotine-induced catecholamine release (IC50: 650 μM). Heptaminol does not inhibit norepinephrine release induced by 59 mM K+ but rather inhibits high-affinity Na+-dependent norepinephrine uptake.
    Heptaminol
  • HY-W726640
    Peraquinsin 35265-50-0 98.65%
    Peraquinsin is a MK2 activator. Peraquinsin can be used for the research of vascular disorder or endothelial barrier disorder. Peraquinsin also is an antihypertensive agent.
    Peraquinsin
  • HY-W745029
    L-Glutathione reduced-d5 98%
    L-Glutathione reduced-d5 (GSH-d5; γ-L-Glutamyl-L-cysteinyl-glycine-d5) is the deuterium labeled L-Glutathione reduced (HY-D0187). L-Glutathione reduced (GSH; γ-L-Glutamyl-L-cysteinyl-glycine) is an endogenous antioxidant and is capable of scavenging oxygen-derived free radicals.
    L-Glutathione reduced-d5
  • HY-W747564
    (+/-)12-HpETE 71030-35-8 99.0%
    (+/-)12-HpETE is a 12-hydroxyicosatetraenoic acid product by lipoxygenase. (+/-)12-HpETE has vasodilator action.
    (+/-)12-HpETE
  • HY-W767865
    Cyclic GMP sodium-13C5 99.03%
    Cyclic GMP sodium-13C5 is the 13C-labeled Cyclic GMP sodium (HY-113469A). Cyclic GMP (cGMP) sodium, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP sodium occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses.
    Cyclic GMP sodium-13C5
  • HY-W870794
    Pirprofen 31793-07-4 ≥99.0%
    Pirprofen (SU 21524) is an orally active non-steroidal anti-inflammatory agent. pirprofen is a reversible prostaglandin synthetase inhibitor. Pirprofen inhibits leucocyte chemotaxis. Pirprofen shows anti-inflammatory, analgesic, antipyretic, ulcerogenic activities. Pirprofen inhibits the secondary phase of platelet aggregation induced by Collagen and Arachidonic acid (HY-109590). Pirprofen induces hepatitis.
    Pirprofen
  • HY-101952S1
    Prostaglandin E2-d9 1356347-42-6 99.5%
    Prostaglandin E2-d9 is the deuterium labeled Prostaglandin E2. Prostaglandin E2 (PGE2) is a hormone-like substance that participate in a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation.
    Prostaglandin E2-d9
  • HY-107372S3
    Uridine triphosphate-d13 dilithium 99.6%
    Uridine triphosphate-d13 (UTP-d13 dilithium; Uridine 5'-triphosphate-d13) dilithium is deuterium labeled Uridine triphosphate (HY-107372). Uridine triphosphate (UTP;Uridine 5'-triphosphate) is a nucleotide that regulates the functions of the pancreas in endocrine and exocrine secretion, proliferation, channels, transporters, and intracellular signaling under normal and disease states.
    Uridine triphosphate-d13 dilithium
  • HY-107372S4
    Uridine triphosphate-15N2 dilithium 98.0%
    Uridine triphosphate-15N2 (UTP-15N2 dilithium; Uridine 5'-triphosphate-15N2) dilithium is 15N labeled Uridine triphosphate (HY-107372). Uridine triphosphate (UTP;Uridine 5'-triphosphate) is a nucleotide that regulates the functions of the pancreas in endocrine and exocrine secretion, proliferation, channels, transporters, and intracellular signaling under normal and disease states.
    Uridine triphosphate-15N2 dilithium
  • HY-109128S2
    Danicamtiv-d3-1 98%
    Danicamtiv-d3-1 (MYK-491-d3-1) is a deuterated labeled Danicamtiv (HY-109128). Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency.
    Danicamtiv-d3-1
  • HY-111372S1
    Finerenone-d5 98%
    Finerenone-d5 (BAY 94-8862-d5) is deuterium labeled Finerenone. Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease.
    Finerenone-d5
  • HY-112499S1
    Menaquinone-7-13C6
    Menaquinone-7-13C6 is the 13C-labeled Menaquinone-7. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs, is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 (Vitamin K2-7) is identified as the most bioactive cofactor for the carboxylation reaction of Gla-proteins . Supplementation with Menaquinone-7 (Vitamin K2-7) is a pharmacological option for activating matrix Gla protein and intervening in the progression of calcific aortic valve stenosis (CAVS).
    Menaquinone-7-13C6
  • HY-113301S1
    Hexacosanoic acid-d4-1 1194984-85-4 98.0%
    Hexacosanoic acid-d4-11 is the deuterium labeled Hexacosanoic acid (HY-113301). Hexacosanoic acid is a very long-chain fatty acid. Abnormally elevated levels of Hexacosanoic acid are closely associated with various diseases, such as X-linked adrenoleukodystrophy, adrenomyeloneuropathy, atherosclerosis, and dementia.
    Hexacosanoic acid-d4-1
  • HY-113301S2
    Hexacosanoic acid-d3 2692624-17-0 ≥99.0%
    Hexacosanoic acid-d3 is deuterium labeled Hexacosanoic acid (HY-113301). Hexacosanoic acid is a very long-chain fatty acid. Abnormally elevated levels of Hexacosanoic acid are closely associated with various diseases, such as X-linked adrenoleukodystrophy, adrenomyeloneuropathy, atherosclerosis, and dementia.
    Hexacosanoic acid-d3
  • HY-141901S1
    DHEA-d5 97453-25-3 98%
    DHEA-d5 (Prasterone-d5; Dehydroisoandrosterone-d5; Dehydroepiandrosterone-d5) is the deuterium labeled DHEA (HY-14650). DHEA (Prasterone) is one of the most abundant steroid hormones. DHEA (Prasterone) mediates its action via multiple signaling pathways involving specific membrane receptors and via transformation into androgen and estrogen derivatives (e.g., androgens, estrogens, 7α and 7β DHEA, and 7α and 7β epiandrosterone derivatives) acting through their specific receptors.
    DHEA-d5
  • HY-15407AS1
    Sacubitril-d4 hemicalcium salt 98.78%
    Sacubitril-d4 hemicalcium salt is the deuterium labeled Sacubitril hemicalcium salt (HY-15407A). Sacubitril hemicalcium salt is a potent NEP inhibitor with an IC50 of 5 nM.
    Sacubitril-d4 hemicalcium salt
  • HY-17504BS1
    Rosuvastatin-d6 sodium 2070009-41-3 99.9%
    Rosuvastatin-d6 sodium is deuterium labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM. Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
    Rosuvastatin-d6 sodium
  • HY-B0141AS1
    Alpha-Estradiol-d2 81586-94-9 99.75%
    Alpha-Estradiol-d2 is the deuterium labeled Alpha-Estradiol. Alpha-Estradiol is a weak estrogen and a 5α-reductase inhibitor which is used as a topical medication in the treatment of androgenic alopecia.
    Alpha-Estradiol-d2
  • HY-P1339AS1
    Orexin B, human-13C18,15N3 TFA
    Orexin B, human-13C18,15N3 (Human orexin B-13C18,15N3) TFA is the 13C- and 15N-labeled Orexin B, human (HY-P1339). Orexin B, human is the agonist for Orexin Receptor, with Kis of 420 nM and 36 nM for OX1 and OX2. Orexin B, human participates in the regulation of appetite, wakefulness, cardiovascular function and neuroendocrine.
    Orexin B, human-13C18,15N3 TFA
Cat. No. Product Name / Synonyms Application Reactivity